CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF

1 . A clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use.

2 . The clottable concentrate of platelet growth factors according to claim 1 , comprising the growth factors PDGF, TGF-β, IGF, EGF, CTGF, bFGF and VEGF.

3 . The clottable concentrate of platelet growth factors according to claim 1 , wherein it is free of risks of blood cells-related transfusion reactions.

4 . The clottable concentrate of platelet growth factors according to claim 1 , further comprising at least one protein selected in the group consisting of fibronectin, vitronectin, thrombospondin, von Willebrand factor and coagulation factors II, V, VII, VIII, IX, X, and XI.

5 . The clottable concentrate of platelet growth factors according to claim 1 , wherein at least one of the following:

(a) the level of cholesterol is lower than 100 mg/dl of the clottable concentrate of platelet growth factors;

(b) the level of triglycerides is lower than 100 mg/dl of the clottable concentrate of platelet growth factors;

(c) the level of HDL is lower than 30 mg/dl of the clottable concentrate of platelet growth factors; and

(d) the level of LDL is lower than 80 mg/dl of the clottable concentrate of platelet growth factors.

6 . A method for preparing a clottable concentrate of platelet growth factors comprising the following steps:

a) contacting a starting platelet concentrate with at least one of: a solvent and a detergent;

b) incubating the starting platelet concentrate with at least one of: the solvent and detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C; and

c) removing at least one of: the solvent and the detergent, by at least one of: oil extraction and chromatography means.

7 . The method of claim 6 , wherein said solvent is selected in the group consisting of di- or trialkylphosphates, di or trialkylphosphates with different alkyl chains.

8 . The method of claim 7 , wherein the solvent is the tri-n-butylphosphate (TnBP).

9 . The method of claim 6 , wherein the detergent is selected in the group consisting of polyoxyethylene derivatives of fatty acids, partial esters of sorbitol anhydrides, non-ionic detergents, sodium deoxycholate and sulfobetaines.

10 . The method of claim 9 , wherein the detergent is one of: Triton X-45, Triton X-100 and Tween 80.

11 . The method of claim 6 , wherein the final concentration of each of the solvent and/or detergent ranges from 0.2 to 5% in volume with respect to the volume of the starting platelets concentrate.

12 . The method of claim 6 , wherein the platelets concentrate is contacted either with one of: (a) 2% TnBP only, and (b) with 1% TnBP and 1% Triton X-45, based on the volume of the starting platelet concentrate.

13 . The method of claim 6 , wherein oil extraction is performed with a pharmaceutical grade oil, the oil being used in an amount of one of the following: (a) from 2 to 20 weight %, (b) from 5 to 15 weight %, and (c) from 5 to 10 weight %, based on the weight of the mixture of the platelet concentrate with at least one of the solvent and detergent.

14 . The method of claim 6 , wherein the chromatography comprises using one of: an hydrophobic (reversed phase) column, and a SDR (Solvent-Detergent removal) hyper D.

15 . The method of claim 6 , wherein the chromatography comprises using at least one of: an anionic and and/or cationic chromatographic column.

16 . The method of claim 6 , further comprising a further step (c1) wherein the step (c1) comprises at least one: anionic and cationic chromatography separation.

17 . The method of claim 15 , wherein at least one of: (a) the cationic chromatography is a strong cationic chromatography, and (b) the anionic chromatography is a weak anionic chromatography

18 . The method of claim 6 , wherein the step (c) comprises at least one oil extraction, followed by a chromatography on strong cation exchanger, and a chromatography on weak anion exchanger, the strong cation exchanger being preferably a SP-Sepharose and the weak anion exchanger being preferably a DEAE-Sepharose.

19 . The method of claim 6 , comprising a further step d) of concentration, by ultrafiltration on membranes with a cut value of 5000 Daltons or less.

20 . The method of claim 6 , comprising a further step e) of nanofiltration using a 10 to 75-nm pore size filter membrane.

21 - 23 . (canceled)

24 . The method of claim 6 , comprising a further f) step of removing fibrinogen from the mixture of growth factors preferably by adding one of: CaCl 2 and thrombin.

25 - 26 . (canceled)

27 . The use of claim 30 , wherein 0.1 to 1 volume of thrombin, the activity of which ranges from 20 IU/ml to 1000 IU/ml, is mixed with 1 volume of the clottable concentrate of platelet growth factors.

28 . The use of claim 27 , wherein the thrombin is human thrombin.

29 . (canceled)

30 . A use of the clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use according to claim 1 , further comprising at least one of: (a) to form a clot, (b) for bone regeneration or for soft and hard tissue healing, (c) for in vitro cell culture, and (d) ex vivo cell culture.

31 - 32 . (canceled)